Overview

Phase 3 Study of SK-1403

Status:
Completed

Trial end date:
2019-12-21

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy and safety of treatment with SK-1403 for 24 weeks in patients with secondary hyperparathyroidism on maintenance hemodialysis.

Phase:

Phase 3

Details

Lead Sponsor:

Sanwa Kagaku Kenkyusho Co., Ltd.